Skip to main content

Amedisys Aktie - Fundamentalanalyse - Dividendenrendite KGV

Amedisys (ISIN: US0234361089, WKN: 915582) Kursdatum: 22.11.2017 Kurs: 56,370 USD
Beschreibung Daten
Symbol AMED
Marktkapitalisierung 1.901.980.160,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Gesundheitswesen
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2006-12-05 - 4:3 |
Internet www.amedisys.com
Letztes Bilanz Update 01.03.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 22.11.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
40,87 30,55 0,00% 5,06 62,70 51,25 1,32 4,13

Firmenbeschreibung

               16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION                        Net Income (Loss) Attributable to Amedisys, Inc. Common Stockholders (1)    Revenue Net Income (Loss) Attributable to Amedisys, Inc. Basic Diluted  2015:              1st Quarter (2) (3) $301.6 $(35.0) $(1.07) $(1.07)  2nd Quarter (3)  314.1  10.6  0.32  0.32  3rd Quarter (2) (3) (5)  326.4  8.4  0.25  0.25  4th Quarter (3) (4) (5)  338.4  12.9  0.39  0.38    $ 1,280.5 $(3.0) $(0.09) $(0.09)  2014:              1st Quarter (6) (7) $298.7 $(12.4) $(0.39) $(0.39)  2nd Quarter (8) (9)  305.0  7.6  0.24  0.23  3rd Quarter (9) (10)  300.3  8.4  0.26  0.26  4th Quarter (6)  300.5  9.1  0.28  0.28    $ 1,204.5 $12.8 $0.39 $0.39 Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.During the first quarter of 2015, we recorded a non-cash asset impairment charge to write-off the software costs incurred related to the development of AMS3 Home Health and Hospice in the amount of $45.5 million, net of income taxes. During the third quarter of 2015, we recorded a non-cash asset impairment charge related to our corporate headquarters in the amount of $1.2 million, net of income taxes.During each of the four quarters of 2015, we incurred certain costs associated with various legal matters. Net of income taxes, these costs amounted to $1.3 million, $4.8 million, $0.2 million and $(1.1) million for the three-month periods ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015, respectively.During the fourth quarter of 2015, we recorded an accrual related to an OIG Self-Disclosure matter. Net of income taxes, this charge amounted to $3.4 million.During the third and fourth quarters of 2015, we incurred certain costs associated with the implementation of Homecare Homebase. Net of income taxes, these costs amounted to $1.2 million and $1.4 million for the three-month periods ended September 30, 2015 and December 31, 2015, respectively.During the first and fourth quarters of 2014, we recognized non-cash other intangibles impairment charges of $1.4 million and $0.6 million, net of income taxes. During the first quarter of 2014, we recorded charges for the accrual of various relators' attorneys' fees and expenses in connection with the settlement agreement to resolve the U.S. Department of Justice investigation and the Stark Law Self-Referral matter and exit and restructuring activity costs. Net of income taxes, these charges amounted to $2.4 million and $6.1 million, respectively.During the second quarter of 2014, we recorded an accrual related to an OIG Self-Disclosure matter. Net of income taxes, this charge amounted to $0.9 million. Additionally, our results included a software write-off in the amount of $0.9 million, net of income taxes.Our results for the second quarter of 2014, included a gain related to the sale of care centers in the amount of $1.3 million, net of income taxes. Our results for the three months ended September 30, 2014, included a loss related to the disposal of our in-patient facility in the amount of $0.3 million, net of income taxes. During the third quarter of 2014, we recorded a charge related to the write-off of deferred financing fees in the amount of $0.3 million, net of income taxes. 

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.amedisys.com